You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dyslipidemia

Showing 1 - 25 of 2,482
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Epicardial Fat Thickness in Children With Familial Dyslipidemia

Not yet recruiting
  • Dyslipidemia
  • echoCARDIOGRAPHY
  • (no location specified)
Oct 22, 2023

Dyslipidemia Trial in Seoul (Rosuvastatin Immediate-Release Tablet (IRT) 10mg, Rosuvastatin orally disintegrating tablet

Recruiting
  • Dyslipidemia
  • Rosuvastatin Immediate-Release Tablet (IRT) 10mg
  • Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
  • Seoul, Korea, Republic of
    Division of Cardiology, Department of Internal Medicine, Yonsei
Nov 22, 2023

Postoperative Dyslipidemia and Organ Rejection in Transplant

Recruiting
  • Heart Transplant Failure and Rejection
    • Wuhan, China
      Wuhan Union Hospital
    Aug 8, 2023

    Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe

    Not yet recruiting
    • Primary Hypercholesterolemia
    • Mixed Dyslipidemia
    • Bempedoic acid and/or its fixed dose combination with ezetimibe
    • (no location specified)
    Mar 23, 2023

    Dyslipidemias Trial in Ankara (Calisthenic Exercises, Aerobic Exercises)

    Not yet recruiting
    • Dyslipidemias
    • Calisthenic Exercises
    • Aerobic Exercises
    • Ankara, Turkey
      Hacettepe University
    Aug 23, 2023

    A Combination Drug Including Fimasartan and Statins in

    Completed
    • Hypertension and Dyslipidemia
    • Combination drug containing fimasartan and statins
    • Gwangju, Jebong-ro, Jangseong-eup, Jangseong-gun, Korea, Republic of
      Chonnam National University Hospital
    Nov 15, 2022

    Treatment of Newvast® Tab(Atorvastatin) in Korean Dyslipidemia

    Completed
    • Dyslipidemia
    • single arm, single group(No interventional)
    • Seoul, Korea, Republic of
      Hanmi Pharmaceutical Company Limited
    Sep 22, 2022

    Primary Hypercholesterolaemia and Mixed Dyslipidemia Trial in Beijing (JS002, Placebo)

    Not yet recruiting
    • Primary Hypercholesterolaemia and Mixed Dyslipidemia
    • Beijing, Beijing, China
      Peking University Third Hospital
    Nov 17, 2022

    Hypercholesterolemia Trial in Guanzhou (Swisse plus cholesterol capsule, Placebo)

    Not yet recruiting
    • Hypercholesterolemia
    • Swisse plus cholesterol capsule
    • Placebo
    • Guanzhou, Guangdong, China
      SunYat-senU
    Apr 28, 2023

    Hypertriglyceridemia, Dyslipidemia Trial in Campinas (Cipros 10 association, Crestor 10 mg)

    Recruiting
    • Hypertriglyceridemia
    • Dyslipidemia
    • Cipros 10 association
    • Crestor 10 mg
    • Campinas, São Paulo, Brazil
      Allergisa
    Aug 3, 2022

    Dyslipidemia and Diabetic Retinopathy

    Recruiting
    • Diabetic Retinopathy
    • Dyslipidemia
    • 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy
    • Healthy Controls 15 age matched control subjects
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Aug 11, 2022

    OLOMAX for Blood Pressure and Low-density Lipoprotein

    Recruiting
    • Hypertension
    • Dyslipidemias
    • Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
    • Seoul, Korea, Republic of
      Seoul St.Mary's Hospital
    Dec 13, 2022

    Dyslipidemias, Non-Alcoholic Fatty Liver Disease Trial in San Antonio (LY3885125, Placebo)

    Recruiting
    • Dyslipidemias
    • Non-Alcoholic Fatty Liver Disease
    • San Antonio, Texas
      Worldwide Clinical Trials, Early Phase Services LLC
    Aug 18, 2023

    Dyslipidemia, Atherosclerosis, Diabetes, Type 2 Trial (Choline fenofibrate, Policosanol)

    Recruiting
    • Dyslipidemia
    • +2 more
    • Seongnam, Gyeonggi, Korea, Republic of
      SNUBH
    Oct 1, 2022

    Status of Dyslipidemia Following Administration of Statin and

    Recruiting
    • Dyslipidemias
    • Statin+Ezetimibe compound
    • Seoul, Korea, Republic of
      Korea University Guro Hospital
    Nov 7, 2022

    Hypercholesterolemia, Dyslipidemia Trial in Seoul (Ezetimibe/Atorvastatin 10/5 mg, Atorvastatin 5mg, Ezetimibe 10mg)

    Completed
    • Hypercholesterolemia, Dyslipidemia
    • Ezetimibe/Atorvastatin 10/5 mg
    • +7 more
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Jul 24, 2023

    Type 2 Diabetes, Dyslipidemia Trial (BERLIM 25/10 association, EMPAGLIFLOZIN, ROSUVASTATIN CALCIUM)

    Not yet recruiting
    • Type 2 Diabetes Mellitus
    • Dyslipidemia
    • BERLIM 25/10 association
    • +5 more
    • (no location specified)
    Aug 3, 2022

    European and French Guidelines for Management of Dyslipidaemias

    Recruiting
    • Patient With Dyslipidemia
    • Detection of patients with dyslipidemia
    • Montpellier, France
      Uhmontpellier
    Jun 29, 2022

    Dyslipidemias, Hypertension Trial in Daegu (Rosuampin 10/5mg, Rosuampin 20/5mg, Amlodipine/Atorvastatin 5/20mg)

    Completed
    • Dyslipidemias
    • Hypertension
    • Rosuampin 10/5mg
    • +2 more
    • Daegu, Korea, Republic of
      Daegu Catholic Univ. Medical Center
    Oct 10, 2022

    Amlodipine/Atorvastatin/Perindopril Single Pill Combination

    Not yet recruiting
    • Arterial Hypertension
    • HTN
    • Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg
    • +2 more
    • (no location specified)
    Mar 1, 2023

    Dyslipidemia Trial in Japan (Part A:Placebo, Part A:AZD8233, Part B:Placebo)

    Completed
    • Dyslipidemia
    • Part A:Placebo
    • +5 more
    • Chiyoda-ku, Japan
    • +6 more
    Oct 3, 2022

    Nephrotic Syndrome Trial in Dallas (Alirocumab, Alirocumab , Atorvastatin)

    Terminated
    • Nephrotic Syndrome
    • Dallas, Texas
      DallasVAMC
    Aug 17, 2022

    "My A:Care" and "Smart Coach" on Lipid-lowering Treatment

    Recruiting
    • Dyslipidemia
    • My A:care
    • Smart Coach
    • Khon Kaen, Thailand
      Chatlert Mueang Pongchaiyakul
    May 9, 2022

    Inclisiran in Chinese Adult Primary Hypercholesterolemia or

    Recruiting
    • Primary Hypercholesterolemia
    • Mixed Dyslipidemia
    • Inclisiran
    • Haikou, Hainan, China
    • +2 more
    Jun 13, 2022

    Dyslipidemia in Patients at High Risk and Very High Risk of

    Recruiting
    • Secondary Prevention
    • +2 more
    • application
    • Leon, Guanajuato, Mexico
      Umae Cmn T1
    Sep 13, 2022